Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH

SAN DIEGO–(BUSINESS WIRE)—- $GOSS #ERSpublications–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH). The article, entitled “Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arte
Click here to view original post